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Robert Luben, Jeff ery Billheimer, John J P Kastelein, S Matthijs Boekholdt, Kay-Tee Khaw, Nick Wareham, Daniel J Rader
Summary
Background Although HDL cholesterol concentrations are strongly and inversely associated with risk of coronary 
heart disease, interventions that raise HDL cholesterol do not reduce risk of coronary heart disease. HDL cholesterol 
effl  ux capacity—a prototypical measure of HDL function—has been associated with coronary heart disease after 
adjusting for HDL cholesterol, but its eff ect on incident coronary heart disease risk is uncertain.
Methods We measured cholesterol effl  ux capacity and assessed its relation with vascular risk factors and incident 
coronary heart disease events in a nested case-control sample from the prospective EPIC-Norfolk study of 
25 639 individuals aged 40–79 years, assessed in 1993–97 and followed up to 2009. We quantifi ed cholesterol effl  ux 
capacity in 1745 patients with incident coronary heart disease and 1749 control participants free of any cardiovascular 
disorders by use of a validated ex-vivo radiotracer assay that involved incubation of cholesterol-labelled J774 
macrophages with apoB-depleted serum from study participants.
Findings Cholesterol effl  ux capacity was positively correlated with HDL cholesterol concentration (r=0·40; p<0·0001) 
and apoA-I concentration (r=0·22; p<0·0001). It was also inversely correlated with type 2 diabetes (r=–0·18; 
p<0·0001) and positively correlated with alcohol consumption (r=0·12; p<0·0001). In analyses comparing the top 
and bottom tertiles, cholesterol effl  ux capacity was signifi cantly and inversely associated with incident coronary 
heart disease events, independent of age, sex, diabetes, hypertension, smoking and alcohol use, waist:hip ratio, 
BMI, LDL cholesterol concentration, log-triglycerides, and HDL cholesterol or apoA-I concentrations (odds ratio 
0·64, 95% CI 0·51–0·80). After a similar multivariable adjustment the risk of incident coronary heart disease was 
0·80 (95% CI 0·70–0·90) for a per-SD change in cholesterol effl  ux capacity.
Interpretation HDL cholesterol effl  ux capacity might provide an alternative mechanism for therapeutic modulation of 
the HDL pathway beyond HDL cholesterol concentration to help reduce risk of coronary heart disease.
Funding US National Institutes of Health, UK Medical Research Council, Cancer Research UK. 
Copyright © Saleheen et al. Open Acess article disrtibuted under the terms of CC BY-NC-ND.
Introduction
HDL cholesterol is log-linearly and inversely associated 
with risk of coronary heart disease.1,2 Direct anti athero genic 
eff ects of HDL cholesterol or its major protein apoA-I have 
been shown in preclinical studies, including prevention or 
regression of lesions in animal models of atherosclerosis 
after administration of HDL cholesterol or apoA-I.3,4 
However, clinical trials and genetic studies have yielded 
confl icting evidence, suggesting that interventions or 
genetic variants that raise HDL cholesterol concentration 
do not necessarily decrease risk of coronary heart 
disease.5–10 This dis crepancy has encouraged further 
studies of the properties of HDL other than static 
mass-based measures to help understand the mechanisms 
that link HDL-related pathways with coronary heart 
disease.
Cholesterol effl  ux capacity is a measure of the ability 
of HDL to promote cholesterol removal from lipid-laden 
macrophages, the fi rst step in the process of reverse 
cholesterol transport.11 HDL cholesterol effl  ux capacity 
was inversely associated with prevalent risk of coronary 
heart disease in a cross-sectional study.12 However, this 
design has inherent limitations because of the inability 
to rule out any changes in effl  ux capacity or other 
relevant traits (ie, HDL cholesterol concentration) that 
could occur because of ongoing atherosclerosis or an 
acute event in a population with prevalent disease.13 
Indeed, although a subsequent report14 confi rmed a 
signifi cant inverse relationship between cholesterol 
effl  ux capacity and prevalent coronary heart disease, it 
suggested the potential for a positive association with 
incident cardio vascular events. In a population-based 
US cohort study of 132 participants with incident 
cardiovascular disease events (54 with coronary heart 
disease events), cholesterol effl  ux capacity (measured 
with a diff erent assay) was inversely associated with 
incident cardiovascular disease events independent of 
HDL cholesterol concentration.15
Here, we report fi ndings from a study of the asso-
ciation between HDL cholesterol effl  ux capacity and 
incident coronary heart disease in a larger cohort in the 
UK.
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Methods
Study design and participants
We did this nested case-control study with patients 
from the EPIC-Norfolk study,16 a prospective population-
based investigation of 25 693 men and women aged 
40–79 years who live in Norfolk (UK). Participants were 
recruited from general practices. Anthropometric 
characteristics, blood pressure, and lipids were similar 
to those in a typical UK population.16 In a baseline 
survey done between 1993 and 1997, participants 
completed a detailed health and lifestyle questionnaire 
and visited a clinic. Non-fasting blood samples were 
obtained, spun, and separated for long-term storage in 
liquid nitrogen or –80°C freezers. Participants were 
identifi ed as having coronary heart disease during 
follow-up if they were admitted to hospital or died with 
coronary heart disease as an underlying cause, or both.17 
Coronary heart disease was defi ned by codes 410–414 
from the International Classifi cation of Diseases (ninth 
revision),18 and included participants with unstable 
angina, stable angina, and myocardial infarction (fatal 
or not). The Norwich District Health Authority ethics 
committee approved the study, and all participants gave 
written informed consent.
We identifi ed 1745 initially healthy people who later 
developed fatal or non-fatal coronary heart disease up to 
March, 2009. Control participants were initially healthy 
and remained free of any cardiovascular disease during 
follow-up. One control participant per patient with 
coronary heart disease was randomly selected by 
computerised algorithm from the cohort to enable a 
control sample population which broadly matched the 
age–sex distribution of the case population. Controls had 
to have at least as much follow-up time as cases and had to 
be alive during follow-up. We selected 1749 controls for 
whom information was available for all cardiovascular risk 
factors and a serum sample was available for measurement 
of cholesterol effl  ux capacity. All participants were of 
European ancestry.
Procedures
For measurement of cholesterol effl  ux capacity, we used 
a 0·5 mL serum sample, which was stored at –80°C at 
baseline and thawed for re-aliquoting before being sent 
to the University of Pennsylvania on dry ice. All samples 
were shipped (and consequently assayed) in two batches 
with a similar number of cases and controls within each 
batch; all analyses were adjusted for batch number.
We quantifi ed cholesterol effl  ux capacity with use of a 
previously published protocol.12,19 J774 cells, derived from 
a mouse macrophage cell line, were plated and 
radiolabelled with 2 μCi of 3H-cholesterol (Perkin Elmer, 
Waltham, USA) per mL. ABCA1 was upregulated by 6 h 
incubation with 0·3 mmol/L 8-(4-chlorophenylthio)-cyclic 
Research in context
Evidence before this study
Evidence from observational, genetic, and interventional 
studies has been inconsistent about the atheroprotective 
eff ects of HDL cholesterol. 
Added value of the study
We estimated the eff ect of cholesterol effl  ux capacity, a 
parameter of HDL function, on incident coronary heart 
disease risk. We investigated more than 13-times more 
coronary heart disease cases than did previous studies; hence, 
estimating the association of cholesterol effl  ux capacity with 
disease risk with greater confi dence. Our study also examines 
for the fi rst time associations of effl  ux capacity with a range 
of vascular and non-vascular traits. We also assessed the 
associations of HDL cholesterol or apoA-I concentrations with 
incident coronary heart disease risk after adjusting for 
cholesterol effl  ux capacity.
Implications of all the available evidence
Cholesterol effl  ux capacity is signifi cantly and inversely 
associated with incident coronary heart events independent of 
established cardiovascular risk factors and even after adjusting 
for HDL cholesterol or apoA-I concentrations. If cholesterol 
effl  ux capacity is shown to be causally associated with coronary 
heart disease risk through genetic or interventional studies, it 
will provide a new mechanism to alter the HDL pathway 
beyond static HDL concentration to reduce the risk of primary 
coronary events. 
Controls (n=1749) Cases (n=1745) p value
Age (years)* 65·0 (7·81) 66·1 (7·48) <0·0001
Males 1067 (61·0%) 1187 (68·0%) <0·0001
Waist:hip ratio 0·88 (0·09) 0·91 (0·08) <0·0001
BMI 26·08 (3·36) 27·21 (3·89) <0·0001
History of diabetes 88 (5·0%) 269 (15·4%) <0·0001
History of hypertension 259 (14·8%) 642 (36·8%) <0·0001
Systolic blood pressure (mm Hg) 138·06 (17·64) 143·31 (18·76) <0·0001
Diastolic blood pressure (mm Hg) 83·05 (10·72) 85·90 (12·33) <0·0001
Current tobacco user 149 (8·5%) 204 (11·7%) <0·0001
Alcohol (units per week) 7·56 (9·29) 7·11 (10·20) 0·17
Statin use 4 (0·2%) 38 (2·2%) <0·0001
Triglyceride concentration (mmol/L) 1·22 (0·19)† 1·30 (0·19)† <0·0001
Total cholesterol concentration (mmol/L) 6·23 (1·14) 6·38 (1·13) <0·0001
LDL cholesterol concentration (mmol/L) 4·02 (1·01) 4·19 (1·00) <0·0001
ApoB concentration (mmol/L) 0·99 (0·26) 1·05 (0·26) <0·0001
HDL cholesterol concentration (mmol/L) 1·41 (0·41) 1·28 (0·36) <0·0001
ApoA-I concentration (mmol/L) 1·58 (0·32) 1·53 (0·36) <0·0001
Data are mean (SD) or n (%). *Mean exact age. †Geometric mean (SD of log-triglycerides). 
Table 1: Characteristics of participants with or without an incident coronary heart disease event 
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AMP (Sigma-Aldrich, St Louis, USA), because ABCA1-
mediated effl  ux is an important pathway of cholesterol 
effl  ux from macrophages and basal J774 cells have very 
low levels of ABCA1 activity. Subsequently, effl  ux medium 
containing 2·8% apoB-depleted serum was added and the 
effl  ux period was for 4 h. To prepare apoB-depleted 
serum, samples were thawed before apoB precipitation. 
Briefl y, 40 parts polyethylene glycol solution (20% 
polyethylene glycol 8000 molecular weight in 200 mmol/L 
glycine buff er [Fisher Scientifi c, Pittsburg, USA], pH 7·4) 
was added to 100 parts serum and mixed by pipetting, 
then incubated at room temperature for 20 min before 
spinning in a microcentrifuge at 10 000 revolutions per 
min for 30 min at 4°C. ApoB-containing lipoproteins 
were pelleted by this procedure and the supernatant, 
which contained the HDL fraction, was recovered and 
diluted in 14 mmol/L MEM-HEPES (no bicarbonate; 
Fisher Scientifi c, Pittsburg, USA) and 0·15 mmol/L 
cAMP (Sigma-Aldrich, St Louis, USA) to 1·4% (equivalent 
to 1% serum).
We used liquid scintillation counting to quantify the 
effl  ux of radioactive cholesterol from J774 cells. We 
calculated the quantity of radioactive cholesterol 
incorporated into cellular lipids by means of 
isopropanol (Sigma-Aldrich, St Louis, USA) extraction 
of control wells not exposed to patient serum. We 
calculated percentage effl  ux by the formula: (μCi of 
³H-cholesterol in mediums containing 2·8% apoB-
depleted serum – μCi of ³H-cholesterol in serum-free 
mediums) / (μCi of ³H-cholesterol in cells) × 100. We did 
all assays in duplicate. To correct for interassay variation 
across plates, we included a pooled serum control from 
fi ve healthy volunteers on each plate, and we normalised 
values for serum samples from patients to this pooled 
Figure 1: Cross-sectional correlates of cholesterol effl  ux capacity in control participants (n=1749)
Assessed by linear regression analyses adjusted for age, sex, and batch number. From each fi tted regression model, we obtained overall adjusted mean values and 
95% CIs for cholesterol effl  ux capacity within quintiles of continuous markers, or within each category for categorical variables. SBP=systolic blood pressure. 
DBP=diastolic blood pressure. 
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See Online for appendix
value in subsequent analyses. The interassay coeffi  cient 
of variation was 4·5% and the intra-assay coeffi  cient of 
variation was 7%. We measured serum concentrations 
of lipids, apoA-I, and apoB as previously described.17
Statistical analysis
We compared baseline characteristics between incident 
coronary heart disease cases and controls. We log-
transformed triglyceride concentrations. We calculated 
partial correlation coeffi  cients adjusted for age and sex to 
assess correlations between cholesterol effl  ux capacity and 
other traits. We further characterised associations between 
cholesterol effl  ux capacity and other characteristics by 
linear regression analyses adjusted for age, sex, and batch 
number. From each fi tted regression model, we obtained 
overall adjusted mean values and 95% CIs for cholesterol 
effl  ux capacity within quintiles of continuous variables, or 
within each category for categorical variables. We calculated 
odds ratios (ORs) for risk of coronary heart disease by 
unconditional logistic regression, progressively adjusted 
for age, sex, history of diabetes, history of hypertension, 
cigarette use, alcohol intake, BMI, waist:hip ratio, LDL 
cholesterol concentration, log-triglyceride concentration, 
and HDL cholesterol or apoA-I concentration. We 
characterised the shapes of the associations by calculating 
ORs using tertiles of cholesterol effl  ux capacity; we 
estimated the corresponding 95% CIs from fl oating 
absolute variances that represent the amount of information 
underlying each group (including the reference group)20 
and implemented fractional polynomial analyses (single 
level). We did statistical analyses with Stata (version 11). All 
p values were two-tailed, with a p value of less than 
0·01 indicating statistical signifi cance.
Role of the funding source
The funder had no role in study design, data collection, 
analysis, or interpretation, or the writing of the report. 
RS, SJ, and RL had access to all the data. DS, RS, NW, 
and DJR were responsible for the decision to submit for 
publication.
Results
Participants who developed incident coronary heart 
disease were slightly older and more overweight, were 
more likely to have a history of diabetes, hypertension, 
and smoking; had higher triglyceride, LDL cholesterol, 
and apoB concentrations; and had lower HDL cholesterol 
and apoA-I concentrations than did controls (table 1). 
Participants who developed coronary heart disease had 
signifi cantly lower mean cholesterol effl  ux capacity 
(adjusted for age and sex) than did controls (1·17 vs 1·14; 
p=0·005).
In control participants, we recorded a signi fi cant 
positive correlation between cholesterol effl  ux capacity 
and HDL cholesterol (r=0·40, 95% CI 0·36–0·42) and 
between cholesterol effl  ux capacity and apoA-I (r=0·22, 
0·18–0·26; fi gure 1, appendix p 1). We detected a weaker 
positive correlation with total cholesterol (r=0·18, 
0·15–0·22) and LDL cholesterol (r=0·05, 0·02–0·08). We 
also recorded signifi cant positive correlations with 
female sex (r=0·24, 0·20–0·27) and alcohol intake 
(r=0·12, 0·08–0·05), whereas we detected signifi cant 
inverse relationships for waist:hip ratio, BMI, and history 
of diabetes.
In analyses adjusted for age, sex, and batch number, the 
OR for coronary heart disease was 0·56 (95% CI 0·46–0·62) 
in individuals with cholesterol effl  ux capacity in the top 
tertile compared with those in the bottom tertile (table 2). 
After progressive adjustment for various cardiovascular risk 
factors, cholesterol effl  ux capacity remained signifi cantly 
associated with incident coronary heart disease events, 
including HDL cholesterol concentration (table 2, appendix 
p 2). For a per-SD increase in cholesterol effl  ux capacity, the 
Bottom tertile Middle tertile Top tertile* Per-SD increase
Not adjusted 1·00 (0·86–1·16) 0·78 (0·67–0·9) 0·58 (0·48–0·71) 0·70 (0·64–0·78)
Adjusted for age, sex, 
batch number
1·00 (0·86–1·17) 0·79 (0·68–0·92) 0·56 (0·46–0·68) 0·70 (0·62–0·78)
Plus history of diabetes 1·00 (0·85–1·17) 0·83 (0·71–0·96) 0·60 (0·49–0·73) 0·75 (0·67–0·83)
Plus history of 
hypertension
1·00 (0·85–1·18) 0·82 (0·70–0·96) 0·59 (0·48–0·72) 0·75 (0·67–0·83)
Plus cigarette use 1·00 (0·85–1·18) 0·82 (0·71–0·96) 0·59 (0·48–0·73) 0·76 (0·68–0·84)
Plus alcohol use 1·00 (0·85–1·18) 0·84 (0·72–0·98) 0·61 (0·50–0·75) 0·76 (0·68–0·84)
Plus waist:hip ratio and 
BMI
1·00 (0·85–1·18) 0·84 (0·72–0·98) 0·62 (0·51–0·77) 0·80 (0·71–0·90)
Plus LDL cholesterol 1·00 (0·85–1·18) 0·83 (0·71–0·96) 0·59 (0·48–0·73) 0·78 (0·70–0·87)
Plus log-triglycerides 1·00 (0·85–1·18) 0·82 (0·70–0·96) 0·58 (0·47–0·71) 0·78 (0·70–0·87)
Plus HDL cholesterol 1·00 (0·83–1·20) 0·84 (0·73–0·97) 0·64 (0·51–0·80) 0·80 (0·70–0·90)
Data are odds ratio (95% CI). Mean cholesterol effl  ux capacity was 0·83 (SD 0·09) in the bottom tertile, 1·13 (SD 0·09) 
in the middle tertile, and 1·40 (SD 0·09) in the top tertile. We calculated odds ratios for coronary heart disease by 
unconditional logistic regression analyses. The total number of participants was the same for all the models. We 
estimated 95% CIs from fl oating absolute variances that represent the amount of information underlying each group 
(including the reference group).20 *For trend, p<0·0001.
Table 2: Association of cholesterol effl  ux capacity with incident coronary heart disease events
Figure 2: Association of cholesterol effl  ux capacity tertiles with incident 
coronary heart disease risk
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OR for coronary heart disease was 0·80 (0·70–0·90) in the 
fi nal multivariable model adjusted for HDL cholesterol 
concentration. The ORs for coronary heart disease 
progressively decreased across tertiles of cholesterol effl  ux 
capacity (fi gure 2). When we used apoA-I concentrations 
instead of HDL cholesterol concentrations in the fi nal 
multivariable analyses, the OR for coronary heart disease 
risk did not change materially from the baseline model and 
cholesterol effl  ux capacity remained independently 
associated with incident coronary heart disease events 
independent of apoA-I concentration (appendix p 3–4; the 
models shown in appendix p 3–4 were restricted to 
participants who had information for apoA-1 concentration: 
1428 cases and 1749 controls). Analyses using fractional 
polynomial curves suggested a dose-response association 
(although not a perfectly linear association) between 
cholesterol effl  ux capacity and coronary heart disease risk 
independent of HDL cholesterol or apoA-1 concentrations 
(appendix p 5).
We investigated the association of HDL cholesterol and 
apoA-I concentrations with incident coronary heart disease 
events in the same participants in whom we measured 
cholesterol effl  ux capacity. As expected, comparing top 
versus bottom tertiles, both HDL cholesterol and apoA-I 
concentrations were signifi cantly and inversely associated 
with coronary heart disease events independent of 
cardiovascular risk factors (fi gure 3). However, further 
adjustment for cholesterol effl  ux capacity attenuated the 
magnitude of these associations, making them non-
signifi cant (fi gure 3). By contrast, neither adjustment for 
HDL cholesterol nor apoA-I concentrations attenuated the 
association between cholesterol effl  ux capacity and 
coronary heart disease (fi gure 3).
When we analysed cholesterol effl  ux capacity in 
association with incident coronary heart disease events 
across subgroups of cardiovascular risk factors (at a 
signifi cance threshold of p<0·01), we detected no 
signifi cant subgroup interactions. We noted trends for 
interaction (p<0·05) for a stronger relationship of 
cholesterol effl  ux capacity with coronary heart disease 
events in men (compared with women) and in never 
smokers (compared with ever smokers; appendix p 6).
Discussion
We report here the fi rst large-scale prospective population-
based study that has investigated the association of HDL 
cholesterol effl  ux capacity with cardiovascular traits and 
incident coronary heart disease events. We found that 
cholesterol effl  ux capacity is signifi cantly and inversely 
associated with incident coronary heart disease events 
independent of several established cardiovascular risk 
factors and even after adjusting for HDL cholesterol or 
apoA-I concentrations. Conversely, the signifi cant inverse 
association of HDL cholesterol or apoA-I concentrations 
with incident coronary heart disease events became non-
signifi cant when analyses were adjusted for cholesterol 
effl  ux capacity. Additionally, we report that cholesterol 
effl  ux capacity was positively correlated with alcohol 
intake and inversely correlated with type 2 diabetes and 
measures of obesity.
These results help to clarify the relation between 
cholesterol effl  ux capacity and incident coronary events. 
Our results contrast with a previous report14 based on a 
study population ascertained at the time of coronary 
angiography, which concluded that cholesterol effl  ux 
capacity was positively associated with incident coronary 
heart disease events. However, our data are generally 
consistent with a report15 from the Dallas Heart Study that 
showed an inverse association of cholesterol effl  ux 
capacity with risk of incident coronary heart disease. Our 
study extends this previous report in several ways. First, 
our study is much larger than the Dallas study, involving 
13 times the number of incident cardiovascular cases and 
32 times the number of incident coronary heart disease 
cases, which enabled us to quantify the eff ect of cholesterol 
effl  ux capacity on incident chronic heart disease risk and 
to do robust subgroup analyses. Second, whereas the 
cohort in the Dallas Heart Study had a mixed ethnic origin 
profi le and considerably younger participants, we included 
only participants of European descent who were older at 
Figure 3: Association with coronary heart disease
*Age, sex, history of diabetes, history of hypertension, cigarette use, alcohol intake, BMI, waist:hip ratio, LDL cholesterol concentration, log-triglyceride concentration. 
CEC=cholesterol effl  ux capacity. CHD=coronary heart disease. CVD=cardiovascular disease.
Association of CEC and HDL cholesterol with CHD risk mutually adjusted for each other (1745 cases and 1749 controls) 
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baseline. Third, samples in the Dallas Heart Study were 
collected while fasting whereas we measured cholesterol 
effl  ux capacity in randomly collected samples.
The Dallas Heart Study used a newer fl uorescently 
labelled (BODIPY) cholesterol method to assay 
cholesterol effl  ux capacity, in contrast to the more 
established radiolabelled cholesterol assay that we used 
in the present study. A comprehensive analysis12 of the 
radiolabelled cholesterol assay we used showed that 
roughly a third of cholesterol effl  ux is mediated by 
ABCA1. By contrast, analysis of the fl uorescently 
labelled cholesterol assay suggests that a much greater 
proportion of effl  ux is mediated by ABCA1.21 Diff erences 
in the assay methods probably account for the 
diff erences in the correlation of cholesterol effl  ux 
capacity with HDL cholesterol, which in the report of 
the Dallas Heart Study was only 0·07 (consistent with a 
previous study21), whereas in our study it was 0·40 
(consistent with other studies using a similar assay12,19). 
Data for apoA-I concentrations were not reported by the 
Dallas Heart Study; in our study, the correlation of 
cholesterol effl  ux capacity with apoA-I concentration 
was lower than correlation with HDL cholesterol, and 
cholesterol effl  ux capacity remained strongly inversely 
associated with incident coronary heart disease events 
after adjusting for apoA-I concentrations. Overall, 
despite the diff erences in the study populations and the 
cholesterol effl  ux capacity assay methods, the con-
sistency of the major fi ndings of the two studies 
strengthens the conclusion that cholesterol effl  ux 
capacity measured in initially healthy individuals is 
inversely associated with incident coronary heart disease 
events independent of HDL cholesterol concentration. 
The relation between cholesterol effl  ux capacity and 
incident events in patients with pre-existing coronary 
heart disease might be diff erent, and further studies are 
needed to address this issue.
Our study has some limitations. It was not adequately 
powered to assess the shape of the relation between 
cholesterol effl  ux capacity across smaller subdivisions 
such as quintiles in association with coronary heart 
disease risk. Our subgroup analyses provide evidence 
suggestive of eff ect modifi cation by HDL cholesterol 
(p<0·05 but >0·01); the association of cholesterol effl  ux 
capacity with coronary heart disease events seemed to 
be non-linear across tertiles of HDL cholesterol 
concentration. We also recorded suggestive interactions 
for apoA-I, sex, and smoking status (all p<0·05 but 
>0·01); these subgroup analyses show the need for even 
larger studies to characterise in detail the association of 
effl  ux capacity with coronary heart disease events across 
various subgroups with greater confi dence. In the EPIC-
Norfolk cohort, lipid concentrations and cholesterol 
effl  ux capacity were measured in random (generally 
non-fasting) samples. However, analyses in which we 
stratifi ed for time since last meal showed no diff erences 
in cholesterol effl  ux capacity across quartiles of fasting 
time (appendix p 6), suggesting that cholesterol effl  ux 
capacity was not aff ected by postprandial state. We did 
not measure cholesterol effl  ux capacity in repeat 
samples in the same participants at diff erent times and 
thus we could not correct for regression dilution, which 
could have led to underestimation of the association 
between cholesterol effl  ux capacity and incident 
coronary heart disease risk.
Although we have shown an inverse relationship 
between cholesterol effl  ux capacity and risk of incident 
coronary heart disease, the causal nature of this 
relationship is uncertain. Further studies with information 
about genotypes and other traits are needed to exclude 
residual confounding and assess the cause of this 
association through a mendelian randomisation study. 
One such study7 has suggested that HDL cholesterol 
concentrations are not causally relevant in coronary heart 
disease; it is plausible that other functional properties of 
HDL (such as cholesterol effl  ux capacity) might have 
causal relevance in coronary heart disease. If cholesterol 
effl  ux capacity is causally related to coronary heart disease, 
then interventions to increase cholesterol effl  ux capacity 
could be a new treatment approach to reduce the risk of 
coronary heart disease.
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